Predict your next investment

Corporation
HEALTHCARE | Biotechnology
amgen.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

5

Partners & Customers

10

Service Providers

1

About Amgen

Amgen (NASDAQ: AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering human therapeutics. Amgen focuses on areas of high unmet medical need and leverages their biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

Amgen Headquarter Location

One Amgen Center Drive

Thousand Oaks, California, 91320,

United States

805-447-1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Amgen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Amgen in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

M

Medical Devices

484 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Amgen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amgen Rank

Research containing Amgen

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Amgen in 2 CB Insights research briefs, most recently on Aug 19, 2019.

Amgen Investments

7 Investments

Amgen has made 7 investments. Their latest investment was in Neumora Therapeutics as part of their Series A on October 10, 2021.

CBI Logo

Amgen Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/7/2021

Series A

Neumora Therapeutics

$500M

Yes

Undisclosed Venture Investors

4

7/13/2020

Corporate Minority - P2P - II

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2019

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

10/18/2018

Corporate Minority - II

Subscribe to see more

$99M

Subscribe to see more

10

10/4/2017

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/7/2021

7/13/2020

10/31/2019

10/18/2018

10/4/2017

Round

Series A

Corporate Minority - P2P - II

Corporate Minority - P2P

Corporate Minority - II

Series E

Company

Neumora Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$500M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Venture Investors

Sources

4

10

10

10

10

Amgen Portfolio Exits

5 Portfolio Exits

Amgen has 5 portfolio exits. Their latest portfolio exit was BeiGene on November 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/30/2021

IPO - II

4

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

11/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO - II

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Amgen Acquisitions

26 Acquisitions

Amgen acquired 26 companies. Their latest acquisition was TeneoBio on July 27, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/27/2021

$991

Acquired

10

4/16/2021

IPO

$991

$75M

Acq - P2P

14

3/30/2021

Series B

$991

$14.85M

Acquired

11

11/22/2019

Spinoff / Spinout

Subscribe to see more

$991

$99M

Subscribe to see more

10

7/8/2019

IPO

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/27/2021

4/16/2021

3/30/2021

11/22/2019

7/8/2019

Investment Stage

IPO

Series B

Spinoff / Spinout

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Total Funding

$75M

$14.85M

$99M

$99M

Note

Acquired

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

10

14

11

10

10

Amgen Partners & Customers

10 Partners and customers

Amgen has 10 strategic partners and customers. Amgen recently partnered with Verastem on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/20/2021

Partner

Verastem

United States

Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM (Sotorasib) In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766 , Verastem Oncology 's investigational dual RAF/MEK inhibitor , with Amgen 's KRAS inhibitor LUMAKRAS TM in KRAS G12C-mutant non-small cell lung cancer .

2

9/16/2021

Partner

Boehringer Ingelheim

Hungary

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

The new clinical partnership adds to Boehringer Ingelheim 's comprehensive program investigating combinations of its SOS1 : : pan-KRAS inhibitor , BI 1701963 with potentially synergistic approaches

1

8/20/2021

Partner

Howard University

United States

Howard University and Amgen create Academia-Biotech Educational Fellowship

Howard University and Amgen , an independent biotechnology company , have designed an innovative academic-industry partnership meant to greatly expand opportunities for underrepresented minorities in the biotechnology and pharmaceutical industries .

1

6/29/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/9/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/20/2021

9/16/2021

8/20/2021

6/29/2021

6/9/2021

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Verastem

Boehringer Ingelheim

Howard University

Country

United States

Hungary

United States

Subscribe to see more

Subscribe to see more

News Snippet

Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM (Sotorasib) In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766 , Verastem Oncology 's investigational dual RAF/MEK inhibitor , with Amgen 's KRAS inhibitor LUMAKRAS TM in KRAS G12C-mutant non-small cell lung cancer .

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

The new clinical partnership adds to Boehringer Ingelheim 's comprehensive program investigating combinations of its SOS1 : : pan-KRAS inhibitor , BI 1701963 with potentially synergistic approaches

Howard University and Amgen create Academia-Biotech Educational Fellowship

Howard University and Amgen , an independent biotechnology company , have designed an innovative academic-industry partnership meant to greatly expand opportunities for underrepresented minorities in the biotechnology and pharmaceutical industries .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Amgen Service Providers

1 Service Provider

Amgen has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Counsel

General Counsel

Service Provider

Associated Rounds

Acquired

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Amgen Team

29 Team Members

Amgen has 29 team members, including former President, Pablo Cagnoni.

Name

Work History

Title

Status

Frank McCormick

Founder

Former

Kal Patel

Founder

Former

Pablo Cagnoni

Tizona Therapeutics, MPM Capital, and Novartis

President

Former

Luigi Costa

Pureos Bioventures, Nordic NanoVector, and Eli Lilly and Company

President

Former

Stephen J Schoch

Chief Financial Officer

Former

Name

Frank McCormick

Kal Patel

Pablo Cagnoni

Luigi Costa

Stephen J Schoch

Work History

Tizona Therapeutics, MPM Capital, and Novartis

Pureos Bioventures, Nordic NanoVector, and Eli Lilly and Company

Title

Founder

Founder

President

President

Chief Financial Officer

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.